SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone925-272-4999
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Steadymed (NASDAQ:STDY) Frequently Asked Questions
What is Steadymed's stock symbol?
Steadymed trades on the NASDAQ under the ticker symbol "STDY."
How were Steadymed's earnings last quarter?
Steadymed Ltd (NASDAQ:STDY) issued its earnings results on Tuesday, August, 14th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.17. View Steadymed's Earnings History.
What is the consensus analysts' recommendation for Steadymed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steadymed in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Steadymed.
Has Steadymed been receiving favorable news coverage?
Headlines about STDY stock have been trending neutral this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Steadymed earned a news sentiment score of 0.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the stock's share price in the immediate future.
Who are some of Steadymed's key competitors?
Some companies that are related to Steadymed include Advanced Accelerator Application (AAAP), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Auris Medical (EARS), Bioblast Pharma (ORPN), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO), FutureWorld (FWDG) and Impax Laboratories (IPXL).
What other stocks do shareholders of Steadymed own?
Who are Steadymed's key executives?
Steadymed's management team includes the folowing people:
- Mr. Jonathan M. N. Rigby, Pres, CEO & Director (Age 50)
- Mr. David W. Nassif, Exec. VP & CFO (Age 64)
- Mr. Robert Zwolinski, Sr. VP of Operations
- Ms. Marylyn Rigby, Sr. Director of Investor Relations and Marketing
- Mr. Carl Hicks Jr., Editor & Chief of Bephenomental.com
When did Steadymed IPO?
(STDY) raised $56 million in an initial public offering on Friday, March 20th 2015. The company issued 4,300,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.
How do I buy shares of Steadymed?
Shares of STDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Steadymed's official website?
How can I contact Steadymed?
Steadymed's mailing address is 5 OPPENHEIMER STREET, REHOVOT L3, 7670105. The company can be reached via phone at 925-272-4999 or via email at [email protected]
MarketBeat Community Rating for Steadymed (NASDAQ STDY)
MarketBeat's community ratings are surveys of what our community members think about Steadymed and other stocks. Vote "Outperform" if you believe STDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
